Advancements and challenges in tuberculosis drug discovery: A comprehensive overview
Microbial Pathogenesis · 2025
DOI: 10.1016/j.micpath.2024.107074 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Microbial Pathogenesis, 2025. Verfasst von Puja Kumari Agnivesh und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, Telangana, 500037, India. Hauptthemen laut MEDLINE: Antitubercular Agents, Drug Discovery, Mycobacterium tuberculosis. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 163 Literaturangaben. Gefördert von: Department of Biotechnology, Ministry of Science and Technology, India.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biological Sciences, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, Telangana, 500037, India.
- Department of Biological Sciences, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, Telangana, 500037, India. Electronic address: nitin.kalia@niperhyd.ac.in.
Förderung
- Department of Biotechnology, Ministry of Science and Technology, India
Zitieren
APA
Agnivesh, P. K., Roy, A., Sau, S., Kumar, S., & Kalia, N. P. (2025). Advancements and challenges in tuberculosis drug discovery: A comprehensive overview. Microbial Pathogenesis. https://doi.org/10.1016/j.micpath.2024.107074
Vancouver
Agnivesh PK, Roy A, Sau S, Kumar S, Kalia NP. Advancements and challenges in tuberculosis drug discovery: A comprehensive overview. Microbial Pathogenesis. 2025. doi:10.1016/j.micpath.2024.107074
BibTeX
@article{Agnivesh2025,
author = {Agnivesh, Puja Kumari and Roy, Arnab and Sau, Shashikanta and Kumar, Sunil and Kalia, Nitin Pal},
title = {Advancements and challenges in tuberculosis drug discovery: A comprehensive overview},
journal = {Microbial Pathogenesis},
year = {2025},
doi = {10.1016/j.micpath.2024.107074}
}
EUVIMED